| Literature DB >> 27443788 |
Thomas Klonisch1,2,3, Aleksandra Glogowska1, Thatchawan Thanasupawat1, Maxwell Burg1, Jerry Krcek1,2, Marshall Pitz4, Appalaraju Jaggupilli5, Prashen Chelikani5, G William Wong6, Sabine Hombach-Klonisch1,7.
Abstract
We established the role of the GPCR relaxin/insulin-like family peptide receptor 1 (RXFP1 receptor) as a novel active receptor in human glioblastoma (GB), a fatal brain tumour. We identified C1q/TNF-related protein 8 (CTRP8) as a novel agonist of the RXFP1 receptor. CTRP8 enhanced the motility and matrix invasion of GB, and this involved PKC-mediated up-regulation of cathepsin B, a marker for poor prognosis in GB patients. We conclude that the absence of relaxin isoforms does not preclude the activation of the RXFP1 receptor, as the least known member of the CTRP family, CTRP8, can effectively target and activate RXFP1 receptors. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27443788 PMCID: PMC5406291 DOI: 10.1111/bph.13559
Source DB: PubMed Journal: Br J Pharmacol ISSN: 0007-1188 Impact factor: 8.739